The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis - Takeaways - MDSpire

The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis

  • By

  • Martin C Hartz

  • Fabian B Johannessen

  • Torben Harsløf

  • Bente L Langdahl

  • July 16, 2024

  • 0 min

Share

  • 1

    Romosozumab (ROMO) significantly increases bone mineral density (BMD) more than teriparatide (TPTD) in postmenopausal women after 12 months.

  • 2

    The study included 315 postmenopausal women meeting specific criteria for ROMO and TPTD treatment at Aarhus University Hospital.

  • 3

    ROMO demonstrated a lower discontinuation rate and fewer cardiovascular adverse events compared to TPTD.

  • 4

    Treatment-naïve patients showed nonsignificantly higher BMD increases with both ROMO and TPTD compared to previously treated patients.

  • 5

    Both ROMO and TPTD are generally safe, but ROMO is contraindicated in patients with a history of myocardial infarction or stroke.

Original Source(s)

The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis

  • by Martin C Hartz, Fabian B Johannessen, Torben Harsløf, Bente L Langdahl

  • July 16, 2024

Related Content

Cable-Plate augmentation improves the therapeutic effect of intramedullary nailing for AO/OTA type A2.3 intertrochanteric fractures with large coronal fragments: a double-center retrospective study

MAFLD is associated with lower bone mineral density in patients with type 2 diabetes: an exploratory cross-sectional analysis of a potential indirect association with HOMA-IR

Editorial: Metabolic and biomechanical factors in bone fragility: new frontiers in understanding and managing osteoporosis